Excellent Results for MS Drug Plegridy

Biogen Idec has just announced its final first year results of the Phase III trial of its relapsing-remitting multiple sclerosis drug Plegridy. The drug met all primary and secondary endpoints of the trial results indicating that it is very effective at reducing multiple sclerosis (MS) disease activity.
Medical News Today